Clinical Trial Update: A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU) [Phase 2]

View source ↗

Summary

Phase 2 BAYOU trial evaluating durvalumab alone and in combination with olaparib for advanced platinum-ineligible bladder cancer; results were posted in 2022-10…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Urinary Bladder Neoplasms | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-10-26